These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1090 related articles for article (PubMed ID: 16170485)

  • 21. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
    Bussen S; Rempen A; Caffier H
    Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmastectomy electron-beam-rotation irradiation in locally advanced breast cancer prognostic factors of locoregional tumor control.
    Hehr T; Budach W; Durst I; Glocker S; Classen J; Weinmann M; Christ G; Bamberg M
    Strahlenther Onkol; 2002 Nov; 178(11):624-32. PubMed ID: 12426673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?
    Martelli G; Miceli R; De Palo G; Coradini D; Salvadori B; Zucali R; Galante E; Marubini E
    Cancer; 2003 Mar; 97(5):1156-63. PubMed ID: 12599220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axillary lymph node dissection in pT1 breast cancer: a retrospective analysis of 315 patients and review of the literature.
    Witt A; Obwegeser R; Auerbach L; Tempfer C; Yavuz D; Kubista E
    Wien Klin Wochenschr; 2002 Jun; 114(10-11):387-90. PubMed ID: 12708092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
    Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
    Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery.
    Greenberg R; Barnea Y; Schneebaum S; Kashtan H; Kaplan O; Skornik Y
    Isr Med Assoc J; 2003 Sep; 5(9):649-52. PubMed ID: 14509156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive model of axillary lymph node involvement in women with small invasive breast carcinoma: axillary metastases in breast carcinoma.
    Martin C; Cutuli B; Velten M
    Cancer; 2002 Jan; 94(2):314-22. PubMed ID: 11900217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of lymph node status by analysis of prognostic factors and possible indications for elective axillary dissection in T1 breast cancers.
    Guarnieri A; Neri A; Correale PP; Lottini M; Testa M; Mariani F; Tucci E; Megha T; Cintorino M; Carli A
    Eur J Surg; 2001 Apr; 167(4):255-9. PubMed ID: 11354316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cathepsin D: an independent prognostic factor in cancer of the breast].
    Romain S; Muracciole X; Varette I; Bressac C; Brandone H; Martin PM
    Bull Cancer; 1990; 77(5):439-47. PubMed ID: 2400813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
    Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
    Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients.
    Marrelli D; Pinto E; Neri A; Megha T; Gioffrè W; Cioppa T; De Marco G; De Stefano A; Roviello F
    Oncol Rep; 2006 Feb; 15(2):425-9. PubMed ID: 16391864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up.
    Reed W; Bøhler PJ; Sandstad B; Nesland JM
    Breast J; 2004; 10(3):174-80. PubMed ID: 15125740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer.
    Altinyollar H; Berberoğlu U; Gülben K; Irkin F
    J Surg Oncol; 2007 Jun; 95(7):567-71. PubMed ID: 17226805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases.
    Gipponi M; Canavese G; Lionetto R; Catturich A; Vecchio C; Sapino A; Friedman D; Cafiero F
    Eur J Surg Oncol; 2006 Mar; 32(2):143-7. PubMed ID: 16300921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.